WO2019218957A1 - Composé en tant qu'inhibiteur du récepteur 4 activé par la protéase (par4) pour le traitement de l'agrégation plaquettaire - Google Patents

Composé en tant qu'inhibiteur du récepteur 4 activé par la protéase (par4) pour le traitement de l'agrégation plaquettaire Download PDF

Info

Publication number
WO2019218957A1
WO2019218957A1 PCT/CN2019/086558 CN2019086558W WO2019218957A1 WO 2019218957 A1 WO2019218957 A1 WO 2019218957A1 CN 2019086558 W CN2019086558 W CN 2019086558W WO 2019218957 A1 WO2019218957 A1 WO 2019218957A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
acid
group
methoxy
pyridin
Prior art date
Application number
PCT/CN2019/086558
Other languages
English (en)
Chinese (zh)
Inventor
吴俊军
李硕
温晓明
阳华
魏国平
胡允金
钱苏
Original Assignee
深圳信立泰药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳信立泰药业股份有限公司 filed Critical 深圳信立泰药业股份有限公司
Priority to CN201980030133.4A priority Critical patent/CN112074522B/zh
Publication of WO2019218957A1 publication Critical patent/WO2019218957A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention is in the field of chemical pharmaceutical technology, and particularly provides a series of compounds as protease inhibitory receptor 4 (PAR4) inhibitors for treating platelet aggregation and their medical uses.
  • PAR4 protease inhibitory receptor 4
  • a compound or a pharmaceutically acceptable salt thereof, which is a protease activated receptor 4 (PAR4) inhibitor for treating platelet aggregation, has the following structure:
  • the halogen is selected from the group consisting of fluorine, chlorine, bromine, and iodine.
  • the C 1-4 alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl.
  • P is selected from CH, N;
  • R 2 is selected from the group consisting of hydrogen, methoxy, butoxy, methoxyethoxy,
  • an acid addition salt can be obtained by contacting a neutral form of such a compound with a sufficient amount of an acid in a neat solution or a suitable inert solvent.
  • pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, hydrogencarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts including, for example, formic acid, acetic acid, trifluoroacetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, amber Acids, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, cit
  • the compounds of the invention may exist in specific geometric or stereoisomeric forms.
  • the present invention contemplates all such compounds, including the cis and trans isomers, the (-)- and (+)-p-enantiomers, the (R)- and (S)-enantiomers, and the diastereomeric a conformation, a (D)-isomer, a (L)-isomer, and a racemic mixture thereof, and other mixtures, such as enantiomerically or diastereomeric enriched mixtures, all of which belong to It is within the scope of the invention.
  • Additional asymmetric carbon atoms may be present in the substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are included within the scope of the invention.
  • the compounds of the present invention may contain unnatural proportions of atomic isotopes on one or more of the atoms that make up the compound.
  • radiolabeled compounds can be used, such as deuterium (2 H), iodine -125 (125 I) or C-14 (14 C). Alterations of all isotopic compositions of the compounds of the invention, whether radioactive or not, are included within the scope of the invention.
  • Step E Synthesis of 2-bromo-5-[imidazo[1,2-a]pyridin-2-yl]imidazo[2,1-b][1,3,4]thiadiazole
  • 3,5-Dimethoxypyridine (10.00 g, 71.9 mmol) was dissolved in dichloromethane (250.0 mL). Subsequently, diphenylphosphonylhydroxylamine (20.00 g, 85.8 mmol) was added in portions to the above solution. Stir at room temperature for 18 hours.
  • Step C Synthesis of 4-methoxypyrazolo[1,5-a]pyridine-2,3-dicarboxylic acid
  • N,4-Dimethoxy-N-methylpyrazolo[1,5-a]pyridine-2-carboxamide (1.00 g, 4.25 mmol) was dissolved in tetrahydrofuran (30 mL).
  • a saturated aqueous ammonium chloride solution 50 ml was added to the system to quench the reaction. The mixture was extracted with ethyl acetate (200 mL EtOAc).
  • Step A Synthesis of (4,6-dimethoxypyrazolo[1,5-a]pyridin-2-yl)-2-(methylthio)imidazo[2,1-b][1,3 , 4] thiadiazole
  • Step G 6-(4-(Benzyloxy)-6-chloropyrazolo[1,5-a]pyridin-2-yl)-2-bromoimidazo[2,1-b][1,3 , 4] thiadiazole
  • Step I Synthesis of 2-bromo-1-[5,6-dimethoxypyrazolo[1,5-a]pyridin-2-yl]ethan-1-one
  • Step B See Example 1 for details, Step C: 2-bromo-1-(pyridazin-2-yl)ethan-1-one (85 mg, 0.36 mmol), 5-bromo-1,3,4- Thiadiazole-2-amine (128 mg, 0.72 mmol), isopropanol (3.0 mL). 2-Bromo-6-(pyridazin-2-yl)imidazo[2,1-b][1,3,4]thiadiazole (50 mg, 43.5%) was obtained as a brown solid. MS (ESI) M / Z: 319 [M+H + ].
  • Step D Synthesis of 6-(6-chloro-4-(2-((tetrahydro-2H-pyran-4-yl)oxy)ethoxy)pyrazolo[1,5-a]pyridine-2 -yl)-2-methoxyimidazo[2,1-b][1,3,4]thiadiazole
  • Step F Synthesis of 1-(4-(benzyloxy)-6-methoxypyrazolo[1,5-a]pyridin-2-yl)ethanol
  • Step H Synthesis of 1-(4-(benzyloxy)-6-methoxy[1,5-a]pyridin-2-yl)-2-bromoethyl ketone
  • the reaction was quenched by the addition of methanol (10 mL). The reaction solution was warmed to room temperature and concentrated.
  • the crude product was purified by reverse phase column [reverse phase column: C18; mobile phase A: water (containing 0.05% formic acid), mobile phase B: acetonitrile; gradient: 30% acetonitrile to 90% acetonitrile in 8 min; detection wavelength: 254 nm
  • reverse phase column reverse phase column: C18; mobile phase A: water (containing 0.05% formic acid), mobile phase B: acetonitrile; gradient: 30% acetonitrile to 90% acetonitrile in 8 min; detection wavelength: 254 nm
  • the fractions were collected and directly lyophilized.
  • Step L Synthesis of 4-(4-((6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)pyridyl) Zoxao[1,5-a]pyridin-4-yloxy)methyl)-5-methylthiazol-2-yl)morpholine
  • Step D Synthesis of 6-(6-chloro-4-(2-((tetrahydro-2H-pyran-4-yl)methoxy)ethoxy)pyrazolo[1,5-a]pyridine- 2-yl)-2-methoxyimidazo[2,1-b][1,3,4]thiadiazole
  • the separation conditions were as follows, column: X select C18 19 mm * 150 mm; mobile phase: water (containing 0.05% trifluoroacetic acid) and acetonitrile; flow rate: 25 ml / min; gradient: acetonitrile increased from 5% in 7 minutes 100%; detection wavelength: 254 nm. Lyophilized under reduced pressure, purified, and lyophilized to give a white solid (4,6-dimethoxypyrazolo[1,5-a]pyridin-2-yl)-N,N-dimethylimidazo[ 2,1-b][1,3,4]thiadiazol-2-amine (16.1 mg, 22.2%). MS (ESI) M / Z: 345 [M+H + ].
  • Step A Synthesis of 4-(3-(6-chloro-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)pyrazolo[ 1,5-a]pyridin-4-yloxy)propyl)morpholine
  • Step A Ethyl 2-bromothiazole-4-carboxylate (2.00 g, 8.50 mmol) was dissolved in 1,4-dioxane (40.0 mL). Subsequently, triethylamine (3.90 g, 38.6 mmol) and 4-fluoropiperidine hydrochloride (3.60 g, 25.7 mmol) were sequentially added to the above solution. The reaction solution was stirred at room temperature for 4 hours.
  • Step B Ethyl 2-(4-fluorocyclohexyl)thiazole-4-carboxylate (1.00 g, 3.90 mmol) was dissolved in tetrahydrofurane (20.0 mL). Subsequently, lithium borohydride (340 mg, 15.5 mmol) and methanol (500 mg, 15.5 mmol) were added in portions to the above solution. The reaction solution was stirred at room temperature for 5 hours.
  • Step A Methyl-2-bromo-5-methyl-thiazole-4-carboxylic acid (1.00 g, 4.24 mmol) was dissolved in dimethyl sulfoxide (20.0 mL). Subsequently, anhydrous potassium carbonate (2.35 g, 17.0 mmol) and 2-oxa-6-azaspiro[3.3] heptane (851 mg, 8.60 mmol) were sequentially added to the above solution. The reaction solution was stirred at 120 ° C for 24 hours.
  • Step C Azodiyldipiperidine (383 mg, 1.52 mmol) was dissolved in tetrahydrofuran (10.0 mL). Subsequently, tributylphosphine (478 mg, 2.36 mmol) was added to the above solution. After the reaction solution was stirred at room temperature for 20 minutes, 6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazole-6- was further added thereto.
  • Step A Ethyl 2-bromothiazole-4-carboxylate (910 mg, 3.86 mmol) was dissolved in 1,4-dioxane (20.0 mL). Subsequently, triethylamine (1.75 g, 17.3 mmol) was added to the above solution.
  • Step B Ethyl 2-(3-fluoroazetidin-1-yl)thiazole-4-carboxylate (400 mg, 1.74 mmol) was dissolved in THF (20.0 mL). The reaction liquid was cooled to 0 ° C, and lithium borohydride (152 mg, 7.00 mmol) was added portionwise to the above solution. Subsequently, methanol (227 mg, 7.00 mmol) was slowly added dropwise thereto. The reaction solution was slowly warmed to room temperature and stirred for 2 hours.
  • Step A Ethyl 2-bromothiazole-4-carboxylate (2.00 g, 8.51 mmol) was dissolved in 1,4-dioxane (50.0 mL). Subsequently, triethylamine (1.30 g, 12.8 mmol) and morpholine (2.22 g, 25.5 mmol) were successively added to the above solution. The reaction solution was heated to 120 ° C and stirred for 6 hours.
  • Step C Azodiyldipiperidine (1.15 g, 4.56 mmol) was dissolved in tetrahydrofuran (10.0 mL). Subsequently, tributylphosphine (1.44 g, 7.12 mmol) was added dropwise to the above solution. After the reaction solution was stirred at room temperature for 30 minutes, 6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazole-6- was further added thereto.
  • Step A 6-Methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)pyrazolo[1,5- a] Pyridin-4-ol (100 mg, 0.32 mmol) was dissolved in N,N-dimethylformamide (2.0 mL). Subsequently, 3-(bromomethyl)tetrahydrofuran (78 mg, 0.47 mmol) and anhydrous potassium carbonate (131 mg, 0.95 mmol) were added to the above solution. The reaction solution was stirred at room temperature for 2 hours.
  • Step A 2-Bromo-4-((tert-butyldimethylsilyloxy)methyl)-5-methylthiazole (510 mg, 1.58 mmol) was dissolved in tetrahydrofuran (20.0). In milliliters). After cooling the above solution to -78 ° C, n-hexane solution of n-butyllithium (0.85 ml, 2.05 mmol, 2.5 mol / liter) was slowly added dropwise thereto. The reaction solution was stirred at -78 ° C for 30 minutes. Subsequently, tetrahydropyranone (237 mg, 2.37 mmol) in tetrahydrofuran (5.0 ml) was added dropwise thereto. The reaction solution was stirred at -78 ° C for 1 hour.
  • Step B 4-(4-((tert-Butyldimethylsilyloxy)methyl)-5-methylthiazol-2-yl)-tetrahydro-2H-pyran-4-ol (430 mg, 1.25 mmol) was dissolved in tetrahydrofuran (50.0 mL). The reaction solution was stirred at room temperature for 1 hour.
  • Step C Azodiyldipiperidine (496 mg, 1.97 mmol) and tributylphosphine (621 mg, 3.08 mmol) were dissolved in tetrahydrofuran (13.0 mL). Subsequently, 6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)pyrazole [1] was added to the above solution.
  • Step A 2-Bromo-4-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylthiazole (200 mg, 0.62 mmol), mp. 3-(methylamino)propionitrile (79 mg, 0.94 mmol), cesium carbonate (243 mg, 0.75 mmol) and 4,5-bisdiphenylphosphino-9,9-dimethyloxaxime ( 43 mg, 0.07 mmol) was dissolved in 1,4-dioxane (5.0 mL). Subsequently, palladium acetate (14 mg, 0.06 mmol) was added to the above solution. The reaction solution was heated to 100 ° C and stirred for 12 hours.
  • Step B 3-((4-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylthiazol-2-yl)(methyl)amino)propanenitrile (90.0 mg) , 0.28 mmol) was dissolved in tetrahydrofuran (1.0 mL). Subsequently, a solution of tetrabutylammonium fluoride in tetrahydrofuran (0.50 ml, 1.0 mol/liter) was added to the above solution. The reaction solution was stirred at room temperature for 30 minutes.
  • Step C Azodiyldipiperidine (242 mg, 0.96 mmol) was dissolved in tetrahydrofurane (2.0 mL). Subsequently, a solution of tributylphosphine (311 mg, 1.44 mmol) in tetrahydrofuran (1.0 ml) was added to the above solution. After the reaction solution was stirred at room temperature for 30 minutes, 6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazole-6- was further added thereto.
  • Step A 6-Methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)pyrazolo[1,5- a] Pyridine-4-hydroxyl (100 mg, 0.32 mmol) was dissolved in N,N-dimethylformamide (10.0 mL). Subsequently, anhydrous potassium carbonate (87 mg, 0.63 mmol) and 3-bromo-2-(bromomethyl)pyridine (158 mg, 0.64 mmol) were sequentially added to the above solution. The reaction solution was stirred at room temperature for 2 hours.
  • Step A 6-Methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)pyrazolo[1,5- a] Pyridin-4-ol (100 mg, 0.32 mmol) was dissolved in N,N-dimethylformamide (10.0 mL). Subsequently, 3-(bromomethyl)pyridine hydrobromide (160 mg, 0.63 mmol) and anhydrous potassium carbonate (174 mg, 1.26 mmol) were sequentially added to the above solution. The reaction solution was stirred at room temperature for 2 hours.
  • Step A Methyl 2-(2-bromo-5-methylthiazol-4-yl)acetate (776 mg, 3.29 mmol) was dissolved in THF (30.0 mL). After the reaction liquid was cooled to 0 ° C, lithium borohydride (276 mg, 13.1 mmol) was added portionwise. Subsequently, methanol (421 mg, 13.1 mmol) was slowly added dropwise thereto. The reaction solution was stirred at 0 ° C for 2 hours.
  • Step B (2-Bromo-5-methylthiazol-4-yl)methanol (660 mg, 3.17 mmol) was dissolved in dichloromethane (45.0 mL). Subsequently, imidazole (431 mg, 6.35 mmol) and trimethyl-tert-butylchlorosilane (950 mg, 6.35 mmol) were sequentially added to the above solution. The reaction solution was stirred at room temperature for 1 hour.
  • Step C 2-Bromo-4-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylthiazole (380 mg, 1.18 mmol), mp. 2-(3,6-Dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (500 mg, 2.38 mmol), Pd(dppf)Cl 2 (263 mg, 0.36 mmol), cesium carbonate (1.20 g, 3.59 mmol) dissolved in 1,4-dioxane (10.0 mL) and water (1.80 mL) Mixed solution. The reaction system was heated to 100 ° C and stirred overnight.
  • Step D 4-(((tert-Butyldimethylsilyl)oxy)methyl)-2-(3,6-dihydro-2H-pyran-4-yl)-5-methylthiazole (326 mg, 1.00 mmol) was dissolved in tetrahydrofuran (10.0 mL). Subsequently, a solution of tetrabutylammonium fluoride in tetrahydrofuran (2.0 ml, 1.0 mol/liter) was added to the above solution.
  • Step E Azodiyl dipiperidine (572 mg, 2.27 mmol) and tributylphosphine (717 mg, 3.55 mmol) were dissolved in tetrahydrofuran (10.0 mL). Subsequently, 6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)pyrazole [1] was added to the above solution.
  • Step A (2-Bromo-5-methylthiazol-4-yl)methanol (200 mg, 0.96 mmol) was dissolved in 1,4-dioxane (10.0 mL). . Subsequently, azetidine-3-carbonitrile hydrochloride (171 mg, 1.44 mmol), tris(dibenzylideneacetone)dipalladium (44 mg, 0.048 mmol), 4,5 was added to the above solution. Bis-diphenylphosphino-9,9-dimethyloxaxan (55.6 mg, 0.096 mmol) and anhydrous cesium carbonate (939 mg, 2.88 mmol). The reaction solution was heated to 120 ° C and stirred for 2 hours.
  • Step A (2-Bromo-5-methylthiazol-4-yl)methanol (2.00 g, 9.61 mmol) and (E)-3-(4,4,5,5).
  • - tetramethyl-1,3,2-dioxaborolan-2-yl)acrylate (4.35 g, 19.2 mmol) dissolved in 1,4-dioxane (40.0 mL) and Water (8.0 ml) in a mixed solution.
  • anhydrous potassium carbonate (2.66 g, 19.2 mmol
  • tetrakistriphenylphosphine palladium 560 mg, 0.48 mmol
  • Step B Ethyl (E)-3-(4-(hydroxymethyl)-5-methylthiazol-2-yl)acrylate (900 mg, 3.96 mmol) was dissolved in methanol (20.0 mL). Subsequently, palladium on water (900 mg, 10%) was added to the above solution. Subsequently, the reaction system was replaced with hydrogen three times. The reaction solution was stirred at room temperature for 2 hours.
  • Step C Ethyl 3-(4-(hydroxymethyl)-5-methylthiazol-2-yl)propanoate (400 mg, 1.75 mmol) was dissolved in ethanol (2.0 mL) and water (2.0 mL) In a mixed solution. Subsequently, lithium hydroxide monohydrate (366 mg, 8.73 mmol) was added to the above solution. The reaction solution was stirred at room temperature for 2 hours.
  • Step D Dissolving 3-(4-(hydroxymethyl)-5-methylthiazol-2-yl)propanoic acid (200 mg, 0.99 mmol) in N,N-dimethylformamide (2.0 mL) in. Subsequently, methylaminoacetonitrile hydrochloride (130 mg, 1.19 mmol), O-(7-azabenzotriazol-1-yl)-N,N,N',N' was sequentially added to the above solution. Tetramethylurea hexafluorophosphate (570 mg, 1.49 mmol) and N,N-diisopropylethylamine (390 mg, 2.98 mmol). The reaction solution was stirred at room temperature for 1 hour.
  • the crude product was purified by high pressure liquid chromatography, and the separation conditions were as follows: column; XBridge Shield RP18 OBD Column, 5 um, 19*150 mm mobile phase: A: water (containing 0.1% ammonium hydrogencarbonate), B: acetonitrile. Flow rate: 25 ml/min, gradient: 5 minutes from 25% acetonitrile to 55% acetonitrile.
  • the product was collected and lyophilized to give N-(cyanomethyl)-3-(4-((6-methoxy-2-(2-methoxyimidazo[2,1-b]) as a white solid.
  • Step A 2-Bromo-4-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylthiazole (1.00 g, 3.12 mmol), mp. 3-(ethylamino)propionitrile (610 mg, 6.22 mmol), tris(dibenzylideneacetone)dipalladium (143 mg, 9.35 mmol), 4,5-bisdiphenylphosphine-9,9 -Methyloxaxime (180 mg, 0.31 mmol), anhydrous cesium carbonate (3.05 g, 9.35 mmol) dissolved in toluene (10.0 mL). The reaction solution was heated to 120 ° C and stirred for 2 hours.
  • Step B 3-((4-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylthiazol-2-yl)(ethyl)amino)propanenitrile (240 mg) , 0.71 mmol, dissolved in tetrahydrofuran (10 mL). Subsequently, tetrabutylammonium fluoride (1.42 ml, 1.42 mmol) was added to the above solution. The reaction solution was stirred at room temperature for 1 hour.
  • Step C Azodiyldipiperidine (1.12 g, 4.44 mmol) was dissolved in tetrahydrofuran (7.0 mL). Subsequently, tributylphosphine (1.20 g, 5.56 mmol) was added to the above solution. After the reaction mixture was stirred at room temperature for 30 minutes, 3-(ethyl(4-(hydroxymethyl)-5-methylthiazol-2-yl)amino)propanenitrile (125 mg, 0.56 mmol) was added thereto.
  • Step A (2-Bromo-5-methylthiazol-4-yl)methanol (150 mg, 0.72 mmol), 2-(azetidin-3-yl)acetonitrile at room temperature under nitrogen. (143 mg, 1.08 mmol), tris(dibenzylideneacetone)dipalladium (33 mg, 0.04 mmol), anhydrous cesium carbonate (704 mg, 2.16 mmol) and 4,5-bisdiphenylphosphine -9,9-Dimethyloxanthene (42 mg, 0.07 mmol) was dissolved in 1,4-dioxane (10.0 mL). The reaction was heated to 120 ° C and stirred overnight.
  • Step B Azodiyldipiperidine (478 mg, 2.36 mmol) and tributylphosphine (378 mg, 1.51 mmol) were dissolved in tetrahydrofuran (2.0 mL). Subsequently, 6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)pyrazole [1] was added to the above solution.
  • the preparation conditions were as follows: Column: XBridge Prep OBD C18 19mm *250mm, 5um; mobile phase: water (containing 10 mmol/L ammonium bicarbonate) and acetonitrile; flow rate: 25 ml/min; gradient: acetonitrile increased from 41% to 50% in 25 minutes; detection wavelength: 254 nm.
  • Step A 3-(4-(Hydroxymethyl)-5-methylthiazol-2-yl)propanoic acid (120 mg, 0.59 mmol) was dissolved in dichloromethane (15.0 mL). Subsequently, methyl ethylamine hydrochloride (143 mg, 1.49 mol), triethylamine (362 mg, 3.58 mmol) and 1-propylphosphoric acid tricyclic anhydride (1.00 ml, 1.34 mmol, 50) were sequentially added to the above solution. % wt of ethyl acetate solution). The reaction solution was stirred at room temperature for 2 hours.
  • Step B Azodiyldipiperidine (342 mg, 1.36 mmol) and tributylphosphine (428 mg, 2.12 mmol) were dissolved in tetrahydrofurane (12.0 mL). Subsequently, 6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)pyrazole [1] was added to the above solution.
  • Step A Dissolving 3-(4-(hydroxymethyl)-5-methylthiazol-2-yl)propanoic acid (400 mg, 1.99 mmol) in N,N-dimethylformamide (50.0 mL) in. Subsequently, N,N-diisopropylethylamine (1.54 g, 11.9 mmol), 3-(methylamino)propionitrile (501 mg, 5.97 mmol) and O-(7-) were sequentially added to the above solution. Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.51 g, 3.98 mmol). The reaction solution was stirred at room temperature for 1 hour.
  • Step B Azodiyldipiperidine (764 mg, 3.03 mmol) was dissolved in tetrahydrofuran (10.0 mL). Subsequently, tributylphosphine (957 mg, 4.73 mmol) was added to the above solution. After the reaction solution was stirred at room temperature for 30 minutes, 6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazole-6- was further added thereto.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé en tant qu'inhibiteur du récepteur 4 activé par protéase (PAR4) pour le traitement de l'agrégation plaquettaire et son application médicale, appartenant au domaine technique des médicaments chimiques.
PCT/CN2019/086558 2018-05-16 2019-05-13 Composé en tant qu'inhibiteur du récepteur 4 activé par la protéase (par4) pour le traitement de l'agrégation plaquettaire WO2019218957A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980030133.4A CN112074522B (zh) 2018-05-16 2019-05-13 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810469296.X 2018-05-16
CN201810469296 2018-05-16

Publications (1)

Publication Number Publication Date
WO2019218957A1 true WO2019218957A1 (fr) 2019-11-21

Family

ID=68539465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/086558 WO2019218957A1 (fr) 2018-05-16 2019-05-13 Composé en tant qu'inhibiteur du récepteur 4 activé par la protéase (par4) pour le traitement de l'agrégation plaquettaire

Country Status (2)

Country Link
CN (1) CN112074522B (fr)
WO (1) WO2019218957A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202315625A (zh) * 2021-08-13 2023-04-16 大陸商深圳信立泰藥業股份有限公司 三聯吡啶二酮化合物或其鹽、包括其藥物組合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265898A (en) * 1978-05-31 1981-05-05 Bayer Aktiengesellschaft Imidazo[2,1-b]-[1,3,4]-thiadiazole compounds, composition and their medicinal use
CN104540835A (zh) * 2012-04-26 2015-04-22 百时美施贵宝公司 用于治疗血小板聚集的作为蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑衍生物
CN104583218A (zh) * 2012-04-26 2015-04-29 百时美施贵宝公司 作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物
CN104640869A (zh) * 2012-04-26 2015-05-20 百时美施贵宝公司 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑和咪唑并哒嗪衍生物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265898A (en) * 1978-05-31 1981-05-05 Bayer Aktiengesellschaft Imidazo[2,1-b]-[1,3,4]-thiadiazole compounds, composition and their medicinal use
CN104540835A (zh) * 2012-04-26 2015-04-22 百时美施贵宝公司 用于治疗血小板聚集的作为蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑衍生物
CN104583218A (zh) * 2012-04-26 2015-04-29 百时美施贵宝公司 作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物
CN104640869A (zh) * 2012-04-26 2015-05-20 百时美施贵宝公司 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑和咪唑并哒嗪衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TEMPLE, K.J. ET AL.: "Identification of the Minimum PAR4 Inhibitor Pharmacophore and Optimization of a Series of 2-Mefhoxy-6-Arylimidazo[2,1-b][1,3,4] Thiadiazoles", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 26, 11 October 2016 (2016-10-11), pages 5481 - 5486, XP029803185, DOI: 10.1016/j.bmcl.2016.10.020 *

Also Published As

Publication number Publication date
CN112074522B (zh) 2022-08-26
CN112074522A (zh) 2020-12-11

Similar Documents

Publication Publication Date Title
AU2022235580B2 (en) (AZA)indole-, benzothiophene-, and benzofuran-3-sulfonamides
TWI825134B (zh) 作為介白素-1活性之抑制劑之磺醯脒（sulfonimidamide）化合物
US12060347B2 (en) Bicyclic heteroaryl substituted compounds
EP2855489B1 (fr) Dérivés d'imidazothiadiazole et d'imidazopyridazine utiles comme inhibiteurs des récepteurs 4 activés par les protéases (par4) pour traiter l'agrégation plaquettaire
KR20230006800A (ko) 세포외 단백질의 분해를 위한 asgpr-결합 화합물
EP1913004B1 (fr) 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones et composés afférents comme agents anti-infectieux
ES2972419T3 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
US9714232B2 (en) Substituted piperazine compounds and methods of use thereof
KR102494647B1 (ko) 비시클릭 헤테로아릴 치환된 화합물
AU2007227203B2 (en) 6,7,8, 9 -tetrahydro- 5H- pyrimido [4, 5-d] azepin-4-yl] -amine derivatives as modulators of TRPVL for the treatment of pain
CN112739690A (zh) 用作smarca2拮抗剂的吡啶-2-酮化合物
CA3202092A1 (fr) Derives de n-(2,3-dihydro-1,4-benzoxazin-4-yl)-3-isopropyl-7-(2,3,5-trifluorophenyl)benzo-thiophene-2-carboxamide et composes similaires pour le traitement d'infections par le ver du cƒur
TW202110813A (zh) 作為ｈｄａｃ抑制劑之３－芳基－４－醯胺基－雙環〔４，５，０〕異羥肟酸
JP2020531447A (ja) Ａｔｒキナーゼの複素環式阻害剤
US9938252B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN104136399B (zh) 泛素活化酶的吡唑并嘧啶基抑制剂
AU2004267052B2 (en) Isothiazoloquinolones and related compounds as anti-infective agents
TW202023550A (zh) 作為vanin抑制劑之雜芳族化合物
KR20070107123A (ko) 항-감염제들로서의 새로운 이소티아졸로퀴놀론들 및 관련화합물들
CN115703792B (zh) 一种并三环类衍生物及其制备方法和医药用途
CA2873971A1 (fr) Pyrrolopyrimidines substituees
EP4019521A1 (fr) Composé d'azahétéroaryle et son utilisation
KR20170083135A (ko) 시르투인 조정제로서의 치환된 가교된 우레아 유사체
WO2024153155A1 (fr) Inhibiteur de wrn double hétérocyclique, son procédé de préparation et son utilisation
CA3237721A1 (fr) Composes de sulfonamide pour traiter des affections neurologiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19802855

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19802855

Country of ref document: EP

Kind code of ref document: A1